In their panel, Peggy and Mark, along with Neil Minkoff, founder of FountainHead HealthCare, provided an update on the current legislative and regulatory landscape for the 340B program and discussed how protections for covered entities will most likely be affected by upcoming decisions in the Senate. The panelists also discussed recent changes by drug manufacturers that restrict access to 340B drug discounts, as well as the actions covered entities are taking to oppose those changes.
The presentation was covered in articles by the Pharmacy Times and Specialty Pharmacy Continuum. Click the links below to read them.
- Pharmacy Times – “Regulatory and Legislative Actions Currently Impacting the 340B Program”
- Specialty Pharmacy Continuum – “340B Covered Entities Facing Deadlines for New Manufacturer Requirements”